Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Cited In for PubMed (Select 18804136)

1.

The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.

Casadevall A, Pirofski LA.

PLoS Pathog. 2015 Apr 23;11(4):e1004717. doi: 10.1371/journal.ppat.1004717. eCollection 2015 Apr. No abstract available.

2.

Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies.

Dutta K, Varshney AK, Franklin MC, Goger M, Wang X, Fries BC.

J Biol Chem. 2015 Mar 13;290(11):6715-30. doi: 10.1074/jbc.M114.630715. Epub 2015 Jan 8.

PMID:
25572397
3.

Demographics of animal bite victims & management practices in a tertiary care institute in Mumbai, Maharashtra, India.

Gogtay NJ, Nagpal A, Mallad A, Patel K, Stimpson SJ, Belur A, Thatte UM.

Indian J Med Res. 2014 Mar;139(3):459-62.

4.

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26. doi: 10.1073/pnas.1402074111. Epub 2014 Apr 28.

5.

Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics.

Wilmes GM, Carey KL, Hicks SW, Russell HH, Stevenson JA, Kocjan P, Lutz SR, Quesenberry RS, Shulga-Morskoy SV, Lewis ME, Clark E, Medik V, Cooper AB, Reczek EE.

MAbs. 2014 Jul-Aug;6(4):957-67. doi: 10.4161/mabs.28917. Epub 2014 Apr 23.

6.

Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.

van Dolleweerd CJ, Teh AY, Banyard AC, Both L, Lotter-Stark HC, Tsekoa T, Phahladira B, Shumba W, Chakauya E, Sabeta CT, Gruber C, Fooks AR, Chikwamba RK, Ma JK.

J Infect Dis. 2014 Jul 15;210(2):200-8. doi: 10.1093/infdis/jiu085. Epub 2014 Feb 7.

7.

Back to the future: recombinant polyclonal antibody therapeutics.

Wang XZ, Coljee VW, Maynard JA.

Curr Opin Chem Eng. 2013 Nov;2(4):405-415.

8.

Development of monoclonal antibodies suitable for rabies virus antibody and antigen detection.

Chander V, Singh RP, Verma PC.

Indian J Virol. 2012 Dec;23(3):317-25. doi: 10.1007/s13337-012-0096-x. Epub 2012 Sep 26.

9.

Antibody-based concepts for multipurpose prevention technologies.

Whaley KJ, Zeitlin L.

Antiviral Res. 2013 Dec;100 Suppl:S48-53. doi: 10.1016/j.antiviral.2013.09.027. Epub 2013 Nov 1. Review.

10.

Novel approaches and challenges to treatment of central nervous system viral infections.

Nath A, Tyler KL.

Ann Neurol. 2013 Sep;74(3):412-22. doi: 10.1002/ana.23988. Review.

11.

Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.

Desoubeaux G, Daguet A, Watier H.

MAbs. 2013 Sep-Oct;5(5):626-32. doi: 10.4161/mabs.25300. Epub 2013 Jun 7.

12.

Multiantibody strategies for HIV.

Hiatt A, Zeitlin L, Whaley KJ.

Clin Dev Immunol. 2013;2013:632893. doi: 10.1155/2013/632893. Epub 2013 Jun 6. Review.

13.

Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of In vitro and In vivo studies.

Madhusudana SN, Ashwin BY, Sudarshan S.

Hum Vaccin Immunother. 2013 Sep;9(9):1914-7. doi: 10.4161/hv.25431. Epub 2013 Jun 21.

14.

Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.

Both L, van Dolleweerd C, Wright E, Banyard AC, Bulmer-Thomas B, Selden D, Altmann F, Fooks AR, Ma JK.

FASEB J. 2013 May;27(5):2055-65. doi: 10.1096/fj.12-219964. Epub 2013 Jan 31.

15.

Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.

Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD.

Anal Biochem. 2012 Nov 15;430(2):141-50. doi: 10.1016/j.ab.2012.08.005. Epub 2012 Aug 21.

16.

Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.

Kostense S, Moore S, Companjen A, Bakker AB, Marissen WE, von Eyben R, Weverling GJ, Hanlon C, Goudsmit J.

Antimicrob Agents Chemother. 2012 Jul;56(7):3524-30. doi: 10.1128/AAC.06179-11. Epub 2012 Apr 30.

17.

Passive immune neutralization strategies for prevention and control of influenza A infections.

Ye J, Shao H, Perez DR.

Immunotherapy. 2012 Feb;4(2):175-86. doi: 10.2217/imt.11.167. Review.

18.

Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.

Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD.

Anal Biochem. 2012 Feb 15;421(2):351-61. doi: 10.1016/j.ab.2011.09.030. Epub 2011 Oct 6.

19.

Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, Blair CD.

Virology. 2011 Jun 5;414(2):146-52. doi: 10.1016/j.virol.2011.03.016. Epub 2011 Apr 13.

20.

Molecular Pharming: future targets and aspirations.

Paul M, van Dolleweerd C, Drake PM, Reljic R, Thangaraj H, Barbi T, Stylianou E, Pepponi I, Both L, Hehle V, Madeira L, Inchakalody V, Ho S, Guerra T, Ma JK.

Hum Vaccin. 2011 Mar;7(3):375-82. Epub 2011 Mar 1. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk